NCT05470283View on ClinicalTrials.gov

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
TumorMetastatic MelanomaMelanoma
Interventions
DRUG

OBX-115

Given by IV

DRUG

Acetazolamide

Given by PO

DRUG

Cyclophosphamide

Given by IV

DRUG

Furosemide

Given by IV

DRUG

Mesna

Given by IV

DRUG

Fludarabine Phosphate

Given by IV

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER